TAmiRNA develops biomarker solutions, which significantly improve early detection of serious age-related illnesses such as osteoporosis

Vienna/Atlanta September 16th, 2016: The Austrian spin-off TAmiRNA develops biomarker solutions, which significantly improve early detection of serious age-related illnesses such as osteoporosis. At this years ASBMR meeting in Atlanta (Georgia) TAmiRNA presents the new osteomiRTM test kit – a unique molecular diagnostic kit for detection of osteoporosis.

TAmiRNA,  an Austrian biotech company specialized in the discovery and validation of microRNA biomarkers, has announced the delivery of two new porducts. osteomiRTM is a signature of serum microRNAs that is associated with bone quality. The osteomiRTM microRNA signature is intended to assess the risk of a first fracture in postmenopausal and type-2 diabetic women. This information enables timely interventions and can help to avoid fractures. thrombomiRTM is a signature of plasma microRNAs that are associated with platelet function. The thrombomiR signature is intended to assess treatment response to anti-platelet therapy. This information helps to identify drug-resistant patients, optimize drug dosage and drug efficacy while reducing the risk of bleeding.

TAmiRNA's  mission is to provide validated diagnostic solutions to patients with serious aging-related illnesses. They aim to improve and prolong patient stability, health and quality of life with increasing age. They are specialized in biomarker development using blood-circulating microRNAs – evolutionary conserved regulators of gene expression and cell/tissue function. We develop diagnostic algorithms (“signatures”) based on the logic combination of micro-RNA levels and clinical parameters. We use this approach to provide decision support to doctors, clinical researchers and pharmaceutical companies for diagnosing disease and managing therapeutic treatment.

TAmiRNA is actively involved in R&D projects such as Frailomic and in osteoporosis (OP) and cardiovascular disease (CVD). OP and CVD are multi-factorial illnesses, which means that different tissues and cellular processes are involved during the onset and progression of disease. Using microRNA signatures we aim to decode the contributing disease factors on a personalized level, and to use this knowledge for better diagnosis.

Nike React Element